Modified Grid Laser Photocoagulation for Diffuse Diabetic Macular Edema: Long-term Visual Results

doi:10.1016/S0161-6420(91)32082-7

Ophthalmology

Volume 98, Issue 10, October 1991, Pages 1594-1602

https://doi.org/10.1016/S0161-6420(91)32082-7 Get rights and content

Abstract

The authors reviewed the records of 302 eyes of 185 patients with diffuse diabetic macular edema with or without cystoid macular edema treated with modified grid laser photocoagulation between the years 1981 and 1990. Three years after initial grid treatment, visual acuity was improved in 14.5%, unchanged in 60.9%, and worse in 24.6% of eyes. The average number of treatments per eye was 1.9. These results show that in assessing long-term visual outcome, modified grid laser photocoagulation is an effective modality in maintaining or improving visual acuity in eyes with diffuse diabetic macular edema. The effectiveness demonstrated in this study is without comparison with control subjects with no treatment or comparison with other treatment techniques.

References (24)

R Klein et al.
The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema
Ophthalmology
(1984)
R Klein et al.
The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XI. The incidence of macular edema
Ophthalmology
(1989)
RJ Olk
Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema
Ophthalmology
(1986)
RJ Olk
Argon green (514 nm) versus krypton red (647 nm) modified grid laser photocoagulation for diffuse diabetic macular edema
Ophthalmology
(1990)
GG Striph et al.
Modified grid laser photocoagulation for diabetic macular edema: the effect on the central visual field
Ophthalmology
(1988)
GH Bresnick
Diabetic maculopathy: a critical review highlighting diffuse macular edema
Ophthalmology
(1983)
GH Bresnick
Diabetic macular edema: a review
Ophthalmology
(1986)
JW McMeel et al.
Diabetic maculopathy
Trans Am Acad Ophthalmol Otolaryngol
(1977)
A Patz et al.
Observations in diabetic macular edema
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1
Arch Ophthalmol
(1985)

Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2

Ophthalmology

(1987)

Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report no. 4

Int Ophthalmol Clin

(1987)

Cited by (306)

Restoration of Photoreceptor Outer Segments up to 24 Months after Pars Plana Vitrectomy in Patients with Diabetic Macular Edema
2017, Ophthalmology Retina
To evaluate the ellipsoid zone (EZ) and external limiting membrane (ELM) status on optical coherence tomography images in patients with diabetic macular edema (DME) before and after pars plana vitrectomy (PPV).
Retrospective observational analysis.
Sixty-one eyes of 49 patients with DME.
We retrospectively reviewed the spectral-domain optical coherence tomography images of 61 eyes of 49 patients with DME who were treated with PPV and evaluated the percentage disruption of the EZ and ELM before and up to 24 months after PPV.
Longitudinal changes in visual acuity (VA), central retinal thickness (CRT), and EZ and ELM spectral-domain optical coherence tomography findings in patients with DME.
The logarithm of the minimum angle of resolution VA was 0.477 before PPV and then improved to 0.372 and 0.344 at 12 and 24 months after PPV, respectively (P < 0.005 and P < 0.001, respectively). The CRT was 505.5 μm before PPV and then decreased gradually to 345.0 and 301.4 μm at 12 and 24 months, respectively (P < 0.001 for both). The percentage disruption of the EZ was 29.3% and ELM was 9.6% before PPV and then deteriorated to 41.6% (P < 0.001) and 15.1% (P < 0.05), respectively, 1 month after PPV. The disruption of the EZ and ELM decreased gradually. The percentage disruption of the ELM recovered but did not improve by 24 months, compared with baseline (11.6%; P = 0.875), whereas the percentage disruption of the EZ recovered to baseline by 6 months (29.4%; P = 1.000) and then decreased significantly at 24 months (21.3%; P < 0.05).
Both the EZ and ELM deteriorated after PPV. Whereas the ELM recovered but did not improve by 24 months when compared with baseline, the EZ and VA improved up to 24 months.
The combination of phacoemulsification surgery and intravitreal triamcinolone injection in patients with cataract and diabetic macular edema
2016, Saudi Journal of Ophthalmology
To assess the safety and efficiency of combined phacoemulsification (PHACO) surgery and intravitreal triamcinolone (IVTA) injection with or without macular grid laser photocoagulation in patients with cataract and diabetic macular edema.
This prospective study included 41 eyes of 36 diabetic patients with cataract and coexisting clinically significant macular edema (CSME). After PHACO and IVTA injection eyes were divided into two groups: the laser and IVTA group (Group 1) and only IVTA group (Group 2). Preoperative and postoperative best corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were recorded. Paired sample t-test was used to compare data in the groups and C square test for qualitative variables.
Postoperative BCVA was significantly higher than the initial BCVA during the follow-up period in both groups (p < 0.01). The BCVA 6 months after surgery was significantly higher in group 1 than in group 2 (p < 0.01). There was no statistically significant difference in IOP between two groups preoperatively and postoperatively during the follow-up period (p > 0.05). There was no statistically significant difference between both groups in mean CMT preoperatively and 2nd week, 2nd month and 3rd month after surgery (p > 0.05). The mean CMT 6 months after surgery was statistically significantly lower in group 1 than in group 2 (p < 0.01).
PHACO surgery combined with IVTA injection improves BCVA and provides a decrease in CMT in diabetic patients with CSME. Additional macular grid laser photocoagulation after surgery helps to preserve this improvement in BCVA and decrease in CMT.
Recent Updates on Nanocarriers for Drug Delivery in Posterior Segment Diseases with Emphasis on Diabetic Retinopathy
2024, Current Diabetes Reviews
Changes in Macular Thickness after Laser Treatment for Diabetic Retinopathy
2023, SSRN
Efficacy of 190 mcg fluocinolone acetonide intravitreal implant: microperimetry and OCT real-life data
2023, European Review for Medical and Pharmacological Sciences
Quality of Life in Diabetic Macular Edema
2023, Diabetic Macular Edema

View all citing articles on Scopus

: Presented at the American Academy of Ophthalmology Annual Meeting, Atlanta, Oct/Nov 1990.

^a: Dr. Lee is currently affiliated with the Department of Ophthalmology, New York University Medical Center, New York.

View full text

Modified Grid Laser Photocoagulation for Diffuse Diabetic Macular Edema: Long-term Visual Results

Abstract

Ophthalmology

Ophthalmology

Ophthalmology

Ophthalmology

Ophthalmology

Ophthalmology

Ophthalmology

Diabetic maculopathy

Trans Am Acad Ophthalmol Otolaryngol

Observations in diabetic macular edema

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1

Arch Ophthalmol

Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2

Ophthalmology

Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report no. 4

Int Ophthalmol Clin